Analyst Ratings for Alnylam Pharmaceuticals (ALNY)
ALNY Rating Summary
ALNY Price Target Summary
- Highest: $33.00 (JMP Securities)
- Lowest: $12.00 (Rodman & Renshaw)
- Average: $23.17
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$23.17 (-16.2%)
Avg. $ Target:
$23.17 (-16.2%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/8/2013 | MLV & Co. | Downgrade | Hold (Buy) |
N/A (N/A) |
23.84 | 27.65 | 15.98% | Details |
| 2/8/2013 | JMP Securities | New Coverage | Market Outperform (N/A) |
33.00 (N/A) |
23.84 | 27.65 | 15.98% | Details |
| 12/12/2012 | Piper Jaffray | Upgrade | Overweight (Neutral) |
25.00 (19.00) |
17.99 | 27.65 | 53.7% | Details |
| 7/17/2012 | Leerink Swann » Updated 8/28/2012 |
New Coverage | Outperform (N/A) |
26.00 (N/A) |
19.16 | 27.65 | 44.31% | Details |
| 5/8/2012 | JPMorgan | New Coverage | Overweight (N/A) |
15.00 (N/A) |
9.97 | 27.65 | 177.33% | Details |
| 10/14/2011 | Rodman & Renshaw | New Coverage | Market Outperform (N/A) |
12.00 (N/A) |
7.13 | 27.65 | 287.8% | Details |
| 5/6/2011 | McNicoll Lewis & Vlak | New Coverage | Buy (N/A) |
N/A (N/A) |
9.56 | 27.65 | 189.23% | Details |
| 2/23/2011 | Needham & Company » Updated 2/4/2013 |
Upgrade | Buy (N/A) |
28.00 (20.00) |
11.17 | 27.65 | 147.54% | Details |
| 2/18/2011 | Roth Capital | Upgrade | Buy (N/A) |
N/A (N/A) |
10.70 | 27.65 | 158.41% | Details |
